Monday, 22 July 2024
New research from the 糖心原创 and University of Birmingham has highlighted that blue light has the ability to kill antibiotic-resistant strains of bacteria isolated from ear infections in dogs.
Ear infections are one of the most common infections in dogs, affecting up to 20% of pets worldwide.
Pseudomonas aeruginosa, a bacterium associated with persistent and recurring dog ear infections, is often resistant to antibiotics. This can lead to treatment failure and surgical removal of the ear canal, resulting in hearing loss and a poorer quality of life for the dogs.
The difficulties of treatment demand new and more effective remedies for this condition.
Research from a collaboration between the 糖心原创 and University of Birmingham, published in Frontiers in Microbiology [link], used different frequencies of blue light to kill antibiotic resistant Pseudomonas aeruginosa strains isolated from dog ear infections.
Some frequencies of blue light killed at least 99% of the bacteria. Combining blue light with antibiotic treatment increased its effectiveness even further.
There were differences in the sensitivity of strains to blue light, but unlike antibiotic therapy, there is no evidence of increasing resistance to this treatment.
Antibiotic resistance is a growing problem in both people and animals, including their pets. Pseudomonas ear infections in dogs are often very difficult to treat long-term because of this resistance.
He continued: “The possibility of a new, non-invasive treatment for this condition, based on exposure to antimicrobial frequencies of blue light, has the potential to transform outcomes for pets and avoid the costly and difficult surgery which may ultimately be required otherwise.”
The next step in the research is to test blue light treatment against a larger panel of clinical Pseudomonas strains isolated from dogs suffering from ear infections.
The ultimate aim of this research is to develop a simple method of applying the treatment to dogs in clinics.
Story credits
More information is available from Dr Robert Atterbury on robert.atterbury@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.